IXICO (IXI) Competitors GBX 12.40 +0.15 (+1.22%) As of 07:16 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock IXI vs. SBTX, COS, C4XD, DDDD, SAR, FUM, TRX, AREC, OKYO, and AORShould you be buying IXICO stock or one of its competitors? The main competitors of IXICO include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Sareum (SAR), Futura Medical (FUM), Tissue Regenix Group (TRX), Arecor Therapeutics (AREC), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry. IXICO vs. Its Competitors SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Sareum Futura Medical Tissue Regenix Group Arecor Therapeutics OKYO Pharma AorTech International SkinBioTherapeutics (LON:SBTX) and IXICO (LON:IXI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk. Which has more volatility and risk, SBTX or IXI? SkinBioTherapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, IXICO has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Do institutionals and insiders have more ownership in SBTX or IXI? 16.6% of SkinBioTherapeutics shares are owned by institutional investors. Comparatively, 56.0% of IXICO shares are owned by institutional investors. 20.4% of SkinBioTherapeutics shares are owned by insiders. Comparatively, 30.3% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor SBTX or IXI? In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score. Company Overall Sentiment SkinBioTherapeutics Neutral IXICO Neutral Is SBTX or IXI more profitable? IXICO has a net margin of -31.10% compared to SkinBioTherapeutics' net margin of -237.95%. IXICO's return on equity of -19.14% beat SkinBioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SkinBioTherapeutics-237.95% -115.86% -61.18% IXICO -31.10%-19.14%-10.40% Which has preferable earnings and valuation, SBTX or IXI? IXICO has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkinBioTherapeutics£1.56M21.22-£3.71M-£1.63-8.92IXICO£11.50M1.00-£3.58M-£3.86-3.21 SummaryIXICO beats SkinBioTherapeutics on 8 of the 11 factors compared between the two stocks. Get IXICO News Delivered to You Automatically Sign up to receive the latest news and ratings for IXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IXI vs. The Competition Export to ExcelMetricIXICOBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£11.49M£150.07M£5.76B£3.18BDividend Yield1.27%3.74%3.95%5.04%P/E Ratio-3.213.8531.31166.92Price / Sales1.003,963.95461.30448,413.15Price / Cash2.2513.1937.7627.93Price / Book0.6359.4710.026.35Net Income-£3.58M-£90.99M£3.27B£5.89B7 Day Performance2.20%10.34%3.17%0.76%1 Month Performance7.83%11.74%4.34%49.50%1 Year Performance33.19%303.51%44.11%141.61% IXICO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IXIIXICON/AGBX 12.40+1.2%N/A+33.4%£11.49M£11.50M-3.2189SBTXSkinBioTherapeuticsN/AGBX 14.26-1.6%N/A+13.9%£32.58M£1.56M-8.7711COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106SARSareumN/AGBX 23.79-0.9%N/A-27.0%£29.72MN/A-5.633,211FUMFutura MedicalN/AGBX 9.31-1.2%N/A-73.6%£29.02M£8.68M-7.6812Gap DownTRXTissue Regenix GroupN/AGBX 28.75-0.9%N/A-54.7%£25.92M£31.98M-29.68120ARECArecor TherapeuticsN/AGBX 65+2.4%N/A-27.0%£24.54M£6.04M-2.3010Gap DownOKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383 Related Companies and Tools Related Companies SBTX Competitors COS Competitors C4XD Competitors DDDD Competitors SAR Competitors FUM Competitors TRX Competitors AREC Competitors OKYO Competitors AOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:IXI) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IXICO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share IXICO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access